Literature DB >> 29435779

Therapeutic Options for In-Stent Restenosis.

Charles Nicolais1, Vladimir Lakhter1, Hafeez Ul Hassan Virk2, Partha Sardar3, Chirag Bavishi4, Brian O'Murchu1, Saurav Chatterjee5.   

Abstract

PURPOSE OF REVIEW: In-stent restenosis (ISR) is a complex disease process that became apparent shortly after the introduction of stents into clinical practice. This review seeks to define in-stent restenosis (ISR) as well as to summarize the major treatment options that have been developed and studied over the past two decades. RECENT
FINDINGS: Recent developments in drug-coated balloons and bioresorbable vascular scaffolds have added new potential treatments for ISR. Two recent network meta-analyses performed a head-to-head comparison of all the various treatment modalities in order to identify the best approach to management of ISR. Current data suggests that repeat stenting with second-generation drug-eluting stents is most likely to lead to the best angiographic and clinical outcomes. In situations where repeat stenting is not preferable, drug-coated balloon therapy seems to be a reasonably effective alternative.

Entities:  

Keywords:  Balloon angioplasty; Bare metal stent; Drug-eluting stent; In-stent restenosis; Neo atherosclerosis; Rotational atherectomy

Mesh:

Substances:

Year:  2018        PMID: 29435779     DOI: 10.1007/s11886-018-0952-4

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  55 in total

1.  Long-term outcome and determinants of event-free survival in patients treated with balloon angioplasty for in-stent restenosis.

Authors:  F Alfonso; M J Pérez-Vizcayno; R Hernández; J Goicolea; A Fernández-Ortíz; J Escaned; C Bañuelos; C Fernández; C Macaya
Journal:  Am J Cardiol       Date:  1999-04-15       Impact factor: 2.778

Review 2.  Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis.

Authors:  George C M Siontis; Giulio G Stefanini; Dimitris Mavridis; Konstantinos C Siontis; Fernando Alfonso; María J Pérez-Vizcayno; Robert A Byrne; Adnan Kastrati; Bernhard Meier; Georgia Salanti; Peter Jüni; Stephan Windecker
Journal:  Lancet       Date:  2015-08-15       Impact factor: 79.321

3.  Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter.

Authors:  Bruno Scheller; Christoph Hehrlein; Wolfgang Bocksch; Wolfgang Rutsch; Dariush Haghi; Ulrich Dietz; Michael Böhm; Ulrich Speck
Journal:  N Engl J Med       Date:  2006-11-13       Impact factor: 91.245

4.  A novel approach to treat in-stent restenosis: 6- and 12-month results using the everolimus-eluting bioresorbable vascular scaffold.

Authors:  Peiman Jamshidi; Tobias Nyffenegger; Zaid Sabti; Elefteri Buset; Stefan Toggweiler; Richard Kobza; Florim Cuculi
Journal:  EuroIntervention       Date:  2016-04-20       Impact factor: 6.534

5.  A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis.

Authors:  Seiji Habara; Masashi Iwabuchi; Naoto Inoue; Shigeru Nakamura; Ryuta Asano; Shinsuke Nanto; Yasuhiko Hayashi; Nobuo Shiode; Shigeru Saito; Yuji Ikari; Takeshi Kimura; Joji Hosokawa; Masato Nakamura; Jun-ichi Kotani; Ken Kozuma; Kazuaki Mitsudo
Journal:  Am Heart J       Date:  2013-08-13       Impact factor: 4.749

6.  The clinical impact of routine angiographic follow-up in randomized trials of drug-eluting stents: a critical assessment of "oculostenotic" reintervention in patients with intermediate lesions.

Authors:  Takahiro Uchida; Jeffrey Popma; Gregg W Stone; Stephen G Ellis; Mark A Turco; John A Ormiston; Toshiya Muramatsu; Masato Nakamura; Shinsuke Nanto; Hiroyoshi Yokoi; Donald S Baim
Journal:  JACC Cardiovasc Interv       Date:  2010-04       Impact factor: 11.195

7.  Restenosis in bare metal and drug-eluting stents: distinct mechanistic insights from histopathology and optical intravascular imaging.

Authors:  R A Byrne; M Joner; T Tada; A Kastrati
Journal:  Minerva Cardioangiol       Date:  2012-10       Impact factor: 1.347

Review 8.  In-stent restenosis in the drug-eluting stent era.

Authors:  George D Dangas; Bimmer E Claessen; Adriano Caixeta; Elias A Sanidas; Gary S Mintz; Roxana Mehran
Journal:  J Am Coll Cardiol       Date:  2010-11-30       Impact factor: 24.094

9.  Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial.

Authors:  David R Holmes; Paul Teirstein; Lowell Satler; Michael Sketch; James O'Malley; Jeffery J Popma; Richard E Kuntz; Peter J Fitzgerald; Hong Wang; Eileen Caramanica; Sidney A Cohen
Journal:  JAMA       Date:  2006-03-12       Impact factor: 56.272

10.  Utility of the fractional flow reserve in the evaluation of angiographically moderate in-stent restenosis.

Authors:  Ramon Lopez-Palop; Eduardo Pinar; Iñigo Lozano; Daniel Saura; Francisco Picó; Mariano Valdés
Journal:  Eur Heart J       Date:  2004-11       Impact factor: 29.983

View more
  9 in total

Review 1.  Current Management of In-Stent Restenosis.

Authors:  Ae Young Her; Eun Seok Shin
Journal:  Korean Circ J       Date:  2018-05       Impact factor: 3.243

Review 2.  Drug-Coated Balloon Angioplasty and Debulking for the Treatment of Femoropopliteal In-Stent Restenosis: A Systematic Review and Meta-Analysis.

Authors:  Zhu Tong; Lianrui Guo; Lixing Qi; Shijun Cui; Xixiang Gao; Yang Li; Jianming Guo; Yongquan Gu
Journal:  Biomed Res Int       Date:  2020-06-10       Impact factor: 3.411

Review 3.  Contemporary Management of Stent Failure: Part One.

Authors:  Nikhil Pal; Jehangir Din; Peter O'Kane
Journal:  Interv Cardiol       Date:  2019-02

4.  Drug-eluting balloons versus new generation drug-eluting stents for the management of in-stent restenosis: an updated meta-analysis of randomized studies.

Authors:  Lei Gao; Ya-Bin Wang; Jing Jing; Ming Zhang; Yun-Dai Chen
Journal:  J Geriatr Cardiol       Date:  2019-06       Impact factor: 3.327

5.  lncRNA MALAT1/miR-143 axis is a potential biomarker for in-stent restenosis and is involved in the multiplication of vascular smooth muscle cells.

Authors:  Chen Cao; Wei Zhen; Haibin Yu; Li Zhang; Yiling Liu
Journal:  Open Life Sci       Date:  2021-12-20       Impact factor: 0.938

6.  A neutralizing IL-11 antibody reduces vessel hyperplasia in a mouse carotid artery wire injury model.

Authors:  David Schumacher; Elisa A Liehn; Pakhwan Nilcham; David Castaño Mayan; Chutima Rattanasopa; Kaviya Anand; Gustavo E Crespo-Avilan; Sauri Hernandez-Resendiz; Roshni R Singaraja; Stuart A Cook; Derek J Hausenloy
Journal:  Sci Rep       Date:  2021-10-19       Impact factor: 4.379

7.  Inhibition of VRK1 suppresses proliferation and migration of vascular smooth muscle cells and intima hyperplasia after injury via mTORC1/β-catenin axis.

Authors:  Xiongshan Sun; Weiwei Zhao; Qiang Wang; Jiaqi Zhao; Dachun Yang; Yongjian Yang
Journal:  BMB Rep       Date:  2022-05       Impact factor: 5.041

8.  Incidence and risk factors of in-stent restenosis after percutaneous coronary intervention in patients from southern China.

Authors:  Mingrui Li; Jingyuan Hou; Xiaodong Gu; Ruiqiang Weng; Zhixiong Zhong; Sudong Liu
Journal:  Eur J Med Res       Date:  2022-01-22       Impact factor: 2.175

Review 9.  In Stent Neo-Atherosclerosis: Pathophysiology, Clinical Implications, Prevention, and Therapeutic Approaches.

Authors:  Annunziata Nusca; Michele Mattia Viscusi; Francesco Piccirillo; Aurelio De Filippis; Antonio Nenna; Cristiano Spadaccio; Francesco Nappi; Camilla Chello; Fabio Mangiacapra; Francesco Grigioni; Massimo Chello; Gian Paolo Ussia
Journal:  Life (Basel)       Date:  2022-03-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.